Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia / 中华男科学杂志
National Journal of Andrology
;
(12): 1147-1151, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-256957
ABSTRACT
Tadalafil, as a selective phosphodiesterase type 5 inhibitor (PDE5I), has revolutionized the treatment of erectile dysfunction (ED) in men. Conventional management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), which is highly complex and likely multifactorial, is associated with unwanted side effects. Innovative once-daily tadalafil regimen is effective in treating the signs and symptoms of BPH. In recent trials in men with BPH, tadalafil significantly improved total IPSS over the initial 12 weeks of medication. Moreover, tadalafil is effective in treating both ED and the signs and symptoms of BPH. In this study, we review the current state of this new management strategy for LUTS secondary to BPH, highlighting the published reports on the efficacy and tolerability of tadalafil.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Hyperplasia
/
Carbolines
/
Retrospective Studies
/
Treatment Outcome
/
Therapeutic Uses
/
Drug Therapy
/
Lower Urinary Tract Symptoms
/
Tadalafil
Type of study:
Observational study
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS